Quick Answer
Aspira Women's Health Inc. reported Research And Development Expense of $3.27 million for the year ending 2024.
- Aspira Women's Health Inc. showed a decrease of -19.1% in Research And Development Expense from 2023 to 2024.
- This data is from Aspira Women's Health Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $938.0 thousand | Q3 2010: $1.11 million | Q1 2011: $1.22 million | Q2 2011: $1.63 million | Q3 2011: $1.37 million | Q1 2012: $452.0 thousand | Q2 2012: $1.00 million | Q3 2012: $429.0 thousand | Q1 2013: $484.0 thousand | Q2 2013: $554.0 thousand | Q3 2013: $553.0 thousand | Q1 2014: $1.15 million | Q2 2014: $1.06 million | Q3 2014: $1.26 million | Q1 2015: $1.11 million | Q2 2015: $919.0 thousand | Q3 2015: $874.0 thousand | Q1 2016: $934.0 thousand | Q2 2016: $564.0 thousand | Q3 2016: $370.0 thousand | Q1 2017: $225.0 thousand | Q2 2017: $268.0 thousand | Q3 2017: $192.0 thousand | Q1 2018: $142.0 thousand | Q2 2018: $154.0 thousand | Q3 2018: $129.0 thousand | Q1 2019: $209.0 thousand | Q2 2019: $225.0 thousand | Q3 2019: $340.0 thousand | Q1 2020: $395.0 thousand | Q2 2020: $380.0 thousand | Q3 2020: $595.0 thousand | Q1 2021: $872.0 thousand | Q2 2021: $1.47 million | Q3 2021: $1.52 million | Q1 2022: $1.35 million | Q2 2022: $1.41 million | Q3 2022: $2.16 million | Q1 2023: $1.27 million | Q2 2023: $693.0 thousand | Q3 2023: $998.0 thousand | Q1 2024: $906.0 thousand | Q2 2024: $952.0 thousand | Q3 2024: $908.0 thousand | Q1 2025: $973.0 thousand | Q2 2025: $704.0 thousand | Q3 2025: $739.0 thousand.
- Over the full 15 years of available data (2010 to 2024), Aspira Women's Health Inc.'s Research And Development Expense has declined by 15.1%.
- Historical annual values: Fiscal year 2024: $3.27 million | Fiscal year 2023: $4.04 million | Fiscal year 2022: $5.92 million | Fiscal year 2021: $5.31 million | Fiscal year 2020: $2.10 million | Fiscal year 2019: $1.02 million | Fiscal year 2018: $550.0 thousand | Fiscal year 2017: $837.0 thousand | Fiscal year 2016: $2.17 million | Fiscal year 2015: $3.75 million | Fiscal year 2014: $4.67 million | Fiscal year 2013: $2.60 million | Fiscal year 2012: $2.22 million | Fiscal year 2011: $5.39 million | Fiscal year 2010: $3.85 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: